Skip to content

Definitive Radiation for High-Risk Spine Metastases

A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06165419
Enrollment
26
Registered
2023-12-11
Start date
2023-12-14
Completion date
2026-05-31
Last updated
2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastasis, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Lung Cancer, Metastatic Tumor, Metastatic Tumor of Bone, Metastatic Tumor to the Spine, Spine Metastases

Brief summary

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

Interventions

RADIATIONSBRT to the spine

Stereotactic body radiation therapy (SBRT) administered to spine metastases

Sponsors

The University of Texas Health Science Center at San Antonio
CollaboratorOTHER
Stony Brook University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligible patients must have: * Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease * Metastatic spine involvement documented by imaging * Involvement of maximum 3 contiguous vertebral bodies at the index site * Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids * An evaluation by an radiation oncology and orthopedic spine/neurosurgery attending * ECOG Performance Status of 0-3 Patients are ineligible if they have: * An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12 * Had previous surgery or radiation to address the target spinal metastases * Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)

Design outcomes

Primary

MeasureTime frameDescription
Cumulative incidence of spinal surgery/stabilization within 6 months following SBRT6 monthsAssess the efficacy of spine SBRT alone in controlling spine metastases

Secondary

MeasureTime frameDescription
Changes on Neck Disability index1 months, 3 months, 6 monthsThe Neck Disability Index measures neck pain and disabilities in patients with neck pain, with scores varying from 0 to 50. Lower scores indicate better outcomes, higher scores indicate a worse outcome.
Changes on Oswestry Low Back Disability Questionnaire1 months, 3 months, 6 monthsThe Oswestry Disability Index measures disability in patients with low back pain, with scores varying from 0 to 50. Lower scores indicate better outcomes, higher scores indicate a worse outcome.
Reduction in epidural tumor volume3 monthsPercent reduction of epidural volume of the treated metastatic lesions
Progression-free survival6 months
Overall survival6 months
Changes on EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire1 months, 3 months, 6 monthsThe EuroQol 5D-5L questionnaire measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each health dimension is scored from 1 to 5, with 1 indicating a better health state, and 5 the worse state possible. Respondents also indicate their overall health status on visual analogue score, with values ranging from 0 (worst health imaginable) to 100 (best health imaginable)

Countries

United States

Contacts

Primary ContactHermina Munoz, RN
hermina.munoz@stonybrookmedicine.edu631-216-2990
Backup ContactLucia Joya
lucia.joya@stonybrookmedicine.edu631-216-2998

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026